Oxford Global is proud to present the Microbiome Discovery and Development Congress taking place on the 12th & 13th June 2017 in Berlin, Germany. This exciting conference showcases world-class speakers discussing novel strategies in microbiome research, challenges of commercialising the microbiome and latest therapeutic trends.
In recent years, there has been a substantial growth in interest in the microbiome. As of yet, no drugs have been approved, however with numerous therapeutics in clinical development the microbiome is set to revolutionise disease therapeutics, diagnostics and preventative medicine. The emerging microbiome market is expected to reach US$658 million by 2023.
Our programme covers the hottest topics in microbiome research, articulating the challenges of the field and considering the latest research trends. Not-to-be-missed sessions include:
The two-day congress offers an interactive platform for high level scientific and business discussions, ensuring valuable networking and interactive sessions. It follows on from the success of its co-located events: our highly anticipated 18th Drug Discovery Summit and 5th Discovery 91AV & Drug Design Congress, which bring together over 250 key opinion leaders and senior industry experts in drug discovery.
In recent years, there has been a substantial growth in interest in the microbiome. As of yet, no drugs have been approved, however with numerous therapeutics in clinical development the microbiome is set to revolutionise disease therapeutics, diagnostics and preventative medicine. The emerging microbiome market is expected to reach US$658 million by 2023.
Our programme covers the hottest topics in microbiome research, articulating the challenges of the field and considering the latest research trends. Not-to-be-missed sessions include:
- Europe First, USA Second: Greg Sieczkiewicz, MPM Capital, will discuss the IP considerations of commercialising the microbiome
- Dirk Gevers, Global Head of the Janssen Human Microbiome Institute, will present an pharma perspective on this burgeoning industry
- Johan van Hylckama Vlieg, VP, Chr-Hansen, covers how best to amplify live bacterial
- Francois-Pierre Martin, Senior Scientist, Nestle Institute of Life Science, will share his work on small molecule microbial drug discovery
The two-day congress offers an interactive platform for high level scientific and business discussions, ensuring valuable networking and interactive sessions. It follows on from the success of its co-located events: our highly anticipated 18th Drug Discovery Summit and 5th Discovery 91AV & Drug Design Congress, which bring together over 250 key opinion leaders and senior industry experts in drug discovery.
